2023 World Conference on Lung Cancer (Posters)-P2.06. Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients

P2.06. Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients - PDF(Abstract)

Back to course

Pdf Summary

This presentation provides an updated analysis of the use of tislelizumab in combination with chemotherapy as a first-line treatment for elderly patients with advanced non-small cell lung cancer (NSCLC). Tislelizumab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), and has shown promise in the treatment of advanced NSCLC.<br /><br />The study included patients aged 70 or older with locally advanced or metastatic NSCLC who did not have certain genetic mutations. The patients received tislelizumab in combination with nab-paclitaxel chemotherapy, with or without platinum, for four cycles followed by tislelizumab maintenance treatment.<br /><br />The primary endpoint of the study was the objective response rate (ORR), while secondary endpoints included progression-free survival (PFS), disease control rate (DCR), overall survival (OS), duration of response (DoR), and safety.<br /><br />The analysis included 39 patients, with a median age of 74 years. The overall median follow-up duration was 20.8 months. In the efficacy analysis set, 22 patients achieved a partial response, resulting in an ORR of 68.8%. The DCR was 96.9%. Median PFS was 14.3 months, and median OS was not reached. The 1-year PFS and OS rates were 52.9% and 89.4%, respectively. The median duration of response was 12.0 months.<br /><br />The most common grade 1-2 treatment-related adverse events (TRAEs) were anemia, increased AST and ALT levels, and decreased platelet count. The most common immune-related adverse events (irAEs) were mild hypothyroidism and pneumonitis.<br /><br />In conclusion, the combination of tislelizumab and chemotherapy as a first-line treatment for elderly patients with advanced NSCLC showed higher ORR, DCR, and meaningful PFS benefit, with a good safety profile. This updated analysis supports the potential of tislelizumab in this patient population.

Asset Subtitle

Banzhou Pan

Meta Tag

Speaker Banzhou Pan

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

tislelizumab

chemotherapy

first-line treatment

elderly patients

advanced non-small cell lung cancer

NSCLC

monoclonal antibody

PD-1

objective response rate

progression-free survival